Multidrug-resistant bacteria in solid organ transplant recipients

Clinical Microbiology and Infection

Volumn 20, Issue s7, 2014, Pages 49-73

  Cervera, C ^a   van Delden, C ^b   Gavalda J ^c   Welte, T ^d   Akova, M ^e   Carratala J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

MDR Enterobacteriaceae; MDR non fermenters; MRSA; Multidrug resistant bacteria; Solid organ transplantation; Vancomycin resistant enterococci

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL ABSCESS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CHOLANGITIS; CYST; ENTEROBACTERIACEAE INFECTION; GRAFT RECIPIENT; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; ORGAN TRANSPLANTATION; REVIEW; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIAL INFECTIONS; IMMUNOCOMPROMISED PATIENT; MULTIDRUG RESISTANCE; OPPORTUNISTIC INFECTIONS;

BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84908204130     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12687     Document Type: Review

References (239)

1. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
2. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-1081.
3. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010; 31(suppl 1): S7-S10.
4. Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J Hosp Infect 2006; 62: 214-218.
5. Linares L, Cofan F, Cervera C et al. Infection-related mortality in a large cohort of renal transplant recipients. Transplant Proc 2007; 39: 2225-2227.
6. Linares L, Cervera C, Cofan F et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc 2007; 39: 2222-2224.
7. Kang CI, Kim SH, Park WB et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 760-766.
8. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-920.
9. Hamandi B, Holbrook AM, Humar A et al. Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients. Am J Transplant 2009; 9: 1657-1665.
10. Candel FJ, Grima E, Matesanz M et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005; 37: 4097-4099.
11. Edmond MB, Wenzel RP. Screening inpatients for MRSA-case closed. N Engl J Med 2013; 368: 2314-2315.
12. Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis 2010; 14(suppl 4): S3-S5.
13. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391-402.
14. Pronovost P, Needham D, Berenholtz S et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355: 2725-2732.
15. Derde LP, Cooper BS, Goossens H et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014; 14: 31-39.
16. Bodro M, Sabe N, Tubau F et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013; 96: 843-849.
17. Holmes NE, Johnson PD, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012; 50: 2548-2552.
18. Alam MR, Donabedian S, Brown W et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol 2001; 39: 3379-3381.
19. Meletis G, Tzampaz E, Sianou E et al. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011; 66: 946-947.
20. Pournaras S, Kristo I, Vrioni G et al. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 2010; 48: 2601-2604.
21. Hermes DM, Pormann Pitt C, Lutz L et al. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. J Med Microbiol 2013; 62 (Pt 8): 1184-1189.
22. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
23. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-624.
24. Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 177-183.
25. Brook NR, White SA, Waller JR, Veitch PS, Nicholson ML. Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant 2003; 3: 614-618.
26. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients-an analysis of USRDS data. Am J Transplant 2007; 7: 653-661.
27. de Rave S, Hansen BE, Groenland TH et al. Heterotopic vs. orthotopic liver transplantation for chronic liver disease: a case-control comparison of short-term and long-term outcomes. Liver Transpl 2005; 11: 396-401.
28. Wang SF, Huang ZY, Chen XP. Biliary complications after living donor liver transplantation. Liver Transpl 2011; 17: 1127-1136.
29. DeOliveira ML, Jassem W, Valente R et al. Biliary complications after liver transplantation using grafts from donors after cardiac death: results from a matched control study in a single large volume center. Ann Surg 2011; 254: 716-722; discussion 22-3.
30. Arnow PM, Zachary KC, Thistlethwaite JR, Thompson KD, Bova JL, Newell KA. Pathogenesis of early operative site infections after orthotopic liver transplantation. Transplantation 1998; 65: 1500-1503.
31. Lo A, Stratta RJ, Hathaway DK et al. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage. Am J Kidney Dis 2001; 38: 132-143.
32. Akhter K, Timpone J, Matsumoto C, Fishbein T, Kaufman S, Kumar P. Six-month incidence of bloodstream infections in intestinal transplant patients. Transpl Infect Dis 2012; 14: 242-247.
33. Guaraldi G, Cocchi S, Codeluppi M et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 2005; 80: 1742-1748.
34. Middleton SJ, Jamieson NV. The current status of small bowel transplantation in the UK and internationally. Gut 2005; 54: 1650-1657.
35. Aguilar-Guisado M, Givalda J, Ussetti P et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007; 7: 1989-1996.
36. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30: 454-460.
37. Luzzaro F, Vigano EF, Fossati D et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002; 21: 849-855.
38. Moreno A, Cervera C, Gavalda J et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant 2007; 7: 2579-2586.
39. de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013; 19: 860-868.
40. Kallen AJ, Mu Y, Bulens S et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304: 641-648.
41. Torre-Cisneros J, Herrero C, Canas E, Reguera JM, De La Mata M, Gomez-Bravo MA. High mortality related with Staphylococcus aureus bacteremia after liver transplantation. Eur J Clin Microbiol Infect Dis 2002; 21: 385-388.
42. Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5: 751-762.
43. Abudu L, Blair I, Fraise A, Cheng KK. Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol Infect 2001; 126: 351-356.
44. Charlebois ED, Bangsberg DR, Moss NJ et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002; 34: 425-433.
45. Jernigan JA, Pullen AL, Partin C, Jarvis WR. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus in an outpatient clinic population. Infect Control Hosp Epidemiol 2003; 24: 445-450.
46. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-198.
47. Santoro-Lopes G, de Gouvea EF, Monteiro RC et al. Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation. Liver Transpl 2005; 11: 203-209.
48. Acton DS, Plat-Sinnige MJ, van Wamel W, de Groot N, van Belkum A. Intestinal carriage of Staphylococcus aureus: how does its frequency compare with that of nasal carriage and what is its clinical impact? Eur J Clin Microbiol Infect Dis 2009; 28: 115-127.
49. Squier C, Rihs JD, Risa KJ et al. Staphylococcus aureus rectal carriage and its association with infections in patients in a surgical intensive care unit and a liver transplant unit. Infect Control Hosp Epidemiol 2002; 23: 495-501.
50. Hashimoto M, Sugawara Y, Tamura S et al. Methicillin-resistant Staphylococcus aureus infection after living-donor liver transplantation in adults. Transpl Infect Dis 2008; 10: 110-116.
51. Bert F, Bellier C, Lassel L et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl 2005; 11: 1093-1099.
52. Russell DL, Flood A, Zaroda TE et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8: 1737-1743.
53. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol 2006; 27: 122-126.
54. Ramos A, Asensio A, Munez E et al. Incisional surgical infection in heart transplantation. Transpl Infect Dis 2008; 10: 298-302.
55. Ramos A, Asensio A, Munez E et al. Incisional surgical site infection in kidney transplantation. Urology 2008; 72: 119-123.
56. Asensio A, Ramos A, Cuervas-Mons V et al. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl 2008; 14: 799-805.
57. Bonatti H, Pruett TL, Brandacher G et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc 2009; 41: 371-374.
58. Manuel O, Lien D, Weinkauf J, Humar A, Cobos I, Kumar D. Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant 2009; 28: 1231-1236.
59. Raboud J, Saskin R, Simor A et al. Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol 2005; 26: 607-615.
60. McBryde ES, Pettitt AN, McElwain DL. A stochastic mathematical model of methicillin resistant Staphylococcus aureus transmission in an intensive care unit: predicting the impact of interventions. J Theor Biol 2007; 245: 470-481.
61. Sadsad R, Sintchenko V, McDonnell GD, Gilbert GL. Effectiveness of Hospital-Wide Methicillin-Resistant Staphylococcus aureus (MRSA) infection control policies differs by Ward Specialty. PLoS ONE 2013; 8: e83099.
62. Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 2006; 103: 5620-5625.
63. Robotham JV, Jenkins DR, Medley GF. Screening strategies in surveillance and control of methicillin-resistant Staphylococcus aureus (MRSA). Epidemiol Infect 2007; 135: 328-342.
64. Huang SS, Septimus E, Kleinman K et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013; 368: 2255-2265.
65. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292.
66. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-e434.
67. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665.
68. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
69. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-771.
70. Murray KP, Zhao JJ, Davis SL et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56: 1562-1569.
71. Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158-163.
72. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 2010; 54: 3161-3169.
73. Miro JM, Entenza JM, Del Rio A et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012; 56: 4511-4515.
74. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013; 3: e003912.
75. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001; 33: 210-219.
76. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
77. Gearhart M, Martin J, Rudich S et al. Consequences of vancomycin-resistant enterococcus in liver transplant recipients: a matched control study. Clin Transplant 2005; 19: 711-716.
78. Papanicolaou GA, Meyers BR, Meyers J et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23: 760-766.
79. Weber SG, Huang SS, Oriola S et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 2007; 35: 73-85.
80. Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003; 37: 921-928.
81. Wang JT, Chen YC, Chang SC et al. Control of vancomycin-resistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital. J Hosp Infect 2004; 58: 97-103.
82. Yoonchang SW, Peck KR, Kim OS et al. Efficacy of infection control strategies to reduce transmission of vancomycin-resistant enterococci in a tertiary care hospital in Korea: a 4-year follow-up study. Infect Control Hosp Epidemiol 2007; 28: 493-495.
83. Montecalvo MA, de Lencastre H, Carraher M et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995; 16: 680-685.
84. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002; 23: 436-440.
85. Lee WG, Park IJ, Jin HY, Park MH. Relapse and reacquisition of rectal colonization by vancomycin-resistant Enterococcus faecium after decolonization. Epidemiol Infect 2010; 138: 1449-1453.
86. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51 (suppl 3): iii23-30.
87. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother 2004; 48: 2144-2148.
88. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707.
89. Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365: 892-900.
90. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58: 734-739.
91. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-2152.
92. Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46: 1142-1151.
93. Koplowicz YB, Schwartz BS, Guglielmo BJ. Development of daptomycin-susceptible, methicillin-resistant Staphylococcus aureus pneumonia during high-dose daptomycin therapy. Clin Infect Dis 2009; 49: 1286-1287.
94. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-1172.
95. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54: 1699-1709.
96. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-844.
97. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-1971.
98. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-844.
99. Pena C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35: 9-16.
100. Reddy P, Malczynski M, Obias A et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007; 45: 846-852.
101. Bert F, Larroque B, Dondero F et al. Risk factors associated with preoperative fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in liver transplant recipients. Transpl Infect Dis 2014; 16: 84-89.
102. Martinez JA, Aguilar J, Almela M et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006; 58: 1082-1085.
103. Katsandri A, Avlamis A, Vasilakopoulou A et al. Risk factors for coexistence of fluoroquinolone resistance and ESBL production among Enterobacteriaceae in a Greek university hospital. J Chemother 2008; 20: 452-457.
104. Martin-Pena A, Cordero E, Fijo J et al. Prospective study of infectious complications in a cohort of pediatric renal transplant recipients. Pediatr Transplant 2009; 13: 457-463.
105. Linares L, Cervera C, Cofan F et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant 2008; 8: 1000-1005.
106. Vidal E, Torre-Cisneros J, Blanes M et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis 2012; 14: 595-603.
107. Linares L, Cervera C, Hoyo I et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc 2010; 42: 2941-2943.
108. Bui KT, Mehta S, Khuu TH et al. Extended spectrum beta-lactamase-producing Enterobacteriaceae infection in heart and lung transplant recipients and in mechanical circulatory support recipients. Transplantation 2014; 97: 590-594.
109. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
110. Clancy CJ, Chen L, Shields RK et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013; 13: 2619-2633.
111. Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transplant Proc 2013; 45: 3389-3393.
112. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012; 14: 198-205.
113. Rana MM, Sturdevant M, Patel G, Huprikar S. Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series. Transpl Infect Dis 2013; 15: E157-E163.
114. Cheng NC, Yu YC, Tai HC et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis 2012; 55: 930-939.
115. Ariza-Heredia EJ, Patel R, Blumberg EA et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis 2012; 14: 229-236.
116. Lubbert C, Becker-Rux D, Rodloff AC et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 2014; 42: 309-316.
117. Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.
118. Tacconelli E, Cataldo MA, Dancer SJ et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014; 20(suppl 1): 1-55.
119. Munoz-Price LS, Hayden MK, Lolans K et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31: 341-347.
120. Kochar S, Sheard T, Sharma R et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30: 447-452.
121. Schwaber MJ, Lev B, Israeli A et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52: 848-855.
122. San-Juan R, Aguado JM, Lumbreras C et al. Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl 2011; 17: 896-904.
123. Saidel-Odes L, Polachek H, Peled N et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012; 33: 14-19.
124. Machado E, Coque TM, Canton R, Baquero F, Sousa JC, Peixe L. Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6')-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 3220-3221.
125. Puerto AS, Fernandez JG, del Castillo Jde D, Pino MJ, Angulo GP. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006; 54: 135-139.
126. Sousa D, Castelo-Corral L, Gutierrez-Urbon JM et al. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 2013; 68: 1917-1925.
127. Elliott E, Brink AJ, van Greune J et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006; 42: e95-e98.
128. Hawser SP, Bouchillon SK, Lascols C et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011; 55: 3917-3921.
129. Poulou A, Voulgari E, Vrioni G et al. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant. J Clin Microbiol 2013; 51: 3176-3182.
130. Tangden T, Adler M, Cars O, Sandegren L, Lowdin E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother 2013; 68: 1319-1326.
131. Hawser SP, Bouchillon SK, Lascols C et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum beta-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2012; 18: 253-259.
132. Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-1902.
133. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-2074.
134. Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients: do we know enough? Transpl Infect Dis 2013; 15: E164-E165.
135. Shi SH, Kong HS, Xu J et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11: 405-412.
136. Johnson LE, D'Agata EM, Paterson DL et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009; 11: 227-234.
137. Botha P, Archer L, Anderson RL et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85: 771-774.
138. Hadjiliadis D, Steele MP, Chaparro C et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26: 834-838.
139. Meachery G, De Soyza A, Nicholson A et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63: 725-731.
140. Alexander BD, Petzold EW, Reller LB et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8: 1025-1030.
141. De Soyza A, Meachery G, Hester KL et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29: 1395-1404.
142. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011; 24: 390-395.
143. Vital D, Hofer M, Benden C, Holzmann D, Boehler A. Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients. Respiration 2013; 86: 25-31.
144. Suhling H, Rademacher J, Greer M et al. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respir J 2013; 42: 542-544.
145. Leung MK, Rachakonda L, Weill D, Hwang PH. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol 2008; 22: 192-196.
146. Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents 2012; 39: 271-272.
147. Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 2011; 36: 723-763.
148. Lim TP, Lee W, Tan TY et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS ONE 2011; 6: e28177.
149. Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012; 57: 1226-1233.
150. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2011; 11: 317.
151. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011; 66 (suppl 3): iii11-18.
152. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55(suppl 3): S173-S180.
153. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (suppl 4): iv67-iv71.
154. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41(suppl 5): S303-S314.
155. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013; 75: 331-336.
156. Stumpf AN, Schmidt C, Hiddemann W, Gerbitz A. High serum concentrations of cyclosporin related to administration of tigecycline. Eur J Clin Pharmacol 2009; 65: 101-103.
157. Polilli E, Ursini T, Mazzotta E et al. Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease. Ann Clin Microbiol Antimicrob 2012; 11: 6.
158. Iwen PC, Mindru C, Kalil AC, Florescu DF. Pediococcus acidilactici endocarditis successfully treated with daptomycin. J Clin Microbiol 2012; 50: 1106-1108.
159. Vernadakis S, Saner FH, Rath PM et al. Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis. Transpl Infect Dis 2009; 11: 346-348.
160. Jacobs JV, Hodges TN, Bremner RM, Walia R, Huang J, Smith MA. Hardware preservation after sternal wound infection in a lung transplant recipient. Ann Thorac Surg 2011; 92: 718-720.
161. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-1681.
162. Abraham G, Finkelberg D, Spooner LM. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother 2008; 42: 719-721.
163. Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55: 599-600.
164. Marino EA, Blanchard E, Samuel R, Gallagher J. Acute interstitial nephritis associated with linezolid. Ann Pharmacother 2009; 43: 1728.
165. Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis 2009; 54: e17-e20.
166. Esposito L, Kamar N, Guilbeau-Frugier C, Mehrenberger M, Modesto A, Rostaing L. Linezolid-induced interstitial nephritis in a kidney-transplant patient. Clin Nephrol 2007; 68: 327-329.
167. Radunz S, Juntermanns B, Kaiser GM et al. Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis 2011; 13: 353-358.
168. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5: 121-125.
169. Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013; 57: 1518-1520.
170. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-e739.
171. Reid GE, Grim SA, Layden JE et al. The use of fosfomycin to treat urinary tract infections in kidney transplant recipients. Transplantation 2013; 96: e12-e14.
172. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004; 286: C913-C922.
173. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14.
174. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-3146.
175. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
176. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121.
177. Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 2013; 57: 1442-1446.
178. Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56: 185-190.
179. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868.
180. Parisi AF, Kaplan MH. Apnea during treatment with sodium colistimethate. JAMA 1965; 194: 298-299.
181. McQuillen MP, Cantor HA, O'Rourke JR. Myasthenic syndrome associated with antibiotics. Trans Am Neurol Assoc 1967; 92: 163-167.
182. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5: 1.
183. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22(suppl 2): 73-78.
184. Jansaker F, Frimodt-Moller N, Sjogren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014; 69: 769-772.
185. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63: 243-245.
186. Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins KL. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 2014; 69: 564-567.
187. Safdar N, Said A, Lucey MR et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 2004; 39: 517-525.
188. Tzakis AG, Gordon RD, Shaw BW Jr, Iwatsuki S, Starzl TE. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation 1985; 40: 667-671.
189. Cremaschi E, Maggiore U, Maccari C, Cademartiri C, Andreoli R, Fiaccadori E. Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED). Minerva Anestesiol 2010; 76: 961-964.
190. Tascini C, Di Paolo A, Polillo M et al. Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin. Antimicrob Agents Chemother 2011; 55: 2458-2459.
191. Mayer M, Tophof C, Opferkuch W. Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. Infection 1988; 16: 225-228.
192. Granai F, Smart HL, Triger DR. A study of the penetration of meropenem into bile using endoscopic retrograde cholangiography. J Antimicrob Chemother 1992; 29: 711-718.
193. Sharara AI, El H II, Mroueh M et al. Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. South Med J 2011; 104: 189-194.
194. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-1229.
195. Lee CH, Yeh PH, Tsai TH. Hepatobiliary excretion of fluconazole and its interaction with cyclosporin A in rat blood and bile using microdialysis. Int J Pharm 2002; 241: 367-373.
196. Weiler S, Fiegl D, MacFarland R et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55: 925-928.
197. Seehofer D, Eurich D, Veltzke-Schlieker W, Neuhaus P. Biliary complications after liver transplantation: old problems and new challenges. Am J Transplant 2013; 13: 253-265.
198. Vrochides D, Fischer SA, Soares G, Morrissey PE. Successful treatment of recurrent cholangitis complicating liver transplantation by Roux-en-Y limb lengthening. Transpl Infect Dis 2007; 9: 327-331.
199. Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004: CD001209.
200. Dinckan A, Aliosmanoglu I, Kocak H et al. Surgical correction of vesico-ureteric reflux for recurrent febrile urinary tract infections after kidney transplantation. BJU Int 2013; 112: E366-E371.
201. Dupont PJ, Psimenou E, Lord R, Buscombe JR, Hilson AJ, Sweny P. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation 2007; 84: 351-355.
202. Eells SJ, Bharadwa K, McKinnell JA, Miller LG. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis 2014; 58: 147-160.
203. Sallee M, Rafat C, Zahar Jr. et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1183-1189.
204. Bennett WM, Elzinga L, Pulliam JP, Rashad AL, Barry JM. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis 1985; 6: 400-404.
205. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 1987; 32: 884-888.
206. Telenti A, Torres VE, Gross JB Jr, Van Scoy RE, Brown ML, Hattery RR. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc 1990; 65: 933-942.
207. Hiyama L, Tang A, Miller LG. Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2006; 47: e9-e13.
208. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 1988; 32: 844-847.
209. Schwab SJ, Weaver ME. Penetration of trimethoprim and sulfamethoxazole into cysts in a patient with autosomal-dominant polycystic kidney disease. Am J Kidney Dis 1986; 7: 434-438.
210. Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int 2011; 24: 627-636.
211. Senechal M, LePrince P, Tezenas du Montcel S et al. Bacterial mediastinitis after heart transplantation: clinical presentation, risk factors and treatment. J Heart Lung Transplant 2004; 23: 165-170.
212. Monkowski DH, Axelrod P, Fekete T, Hollander T, Furukawa S, Samuel R. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis 2007; 9: 114-120.
213. Pasic M, Schaffarczyk R, Hetzer R. Successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a heart transplant recipient. Eur J Cardiothorac Surg 2004; 25: 1127-1128.
214. Swartz TH, Huprikar S, Labombardi V et al. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia. Transpl Infect Dis 2013; 15: E177-E181.
215. Malani PN, Dyke DB, Pagani FD, Armstrong WS, Chenoweth CE. Successful treatment of vancomycin resistant Enterococcus faecium mediastinitis associated with left ventricular assist devices. Ann Thorac Surg 2003; 76: 1719-1720.
216. George RS, Birks EJ, Haj-Yahia S et al. Acinetobacter mediastinitis in a heart transplant patient. Ann Thorac Surg 2006; 82: 715-716.
217. Abid Q, Nkere UU, Hasan A et al. Mediastinitis in heart and lung transplantation: 15 years experience. Ann Thorac Surg 2003; 75: 1565-1571.
218. Sjogren J, Gustafsson R, Dobre M, Koul B, Ingemansson R, Algotsson L. Vacuum-assisted closure therapy in mediastinitis after heart transplantation. J Heart Lung Transplant 2004; 23: 506-507.
219. Verleden GM, Vos R, van Raemdonck D, Vanaudenaerde B. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant 2010; 15: 568-571.
220. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11: 359-365.
221. Hadjiliadis D, Howell DN, Davis RD et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000; 5: 13-19.
222. Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection. Respirology 2013; 18: 22-38.
223. Kroegel C, Hekmat K, Moser A, Happe J, Walther R, Reissig A. Airway complications following lung transplantation - clinic, diagnosis, and interventional management. Pneumologie 2011; 65: 293-307.
224. Berger N, Guggenbichler S, Steurer W et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis 2006; 6: 127.
225. Herrero-Martinez JM, Lumbreras C, Manrique A et al. Epidemiology, risk factors and impact on long-term pancreatic function of infection following pancreas-kidney transplantation. Clin Microbiol Infect 2013; 19: 1132-1139.
226. Nath DS, Gruessner A, Kandaswamy R, Gruessner RW, Sutherland DE, Humar A. Late anastomotic leaks in pancreas transplant recipients - clinical characteristics and predisposing factors. Clin Transplant 2005; 19: 220-224.
227. Buijk SE, Bruining HA. Future directions in the management of tertiary peritonitis. Intensive Care Med 2002; 28: 1024-1029.
228. Martin-Lopez A, Castano-Avila S, Maynar-Moliner FJ, Urturi-Matos JA, Manzano-Ramirez A, Martin-Lopez HP. Tertiary peritonitis: as difficult to define as it is to treat. Cir Esp 2012; 90: 11-16.
229. Dahyot-Fizelier C, Lefeuvre S, Laksiri L et al. Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Clin Pharmacokinet 2010; 49: 323-334.
230. Karjagin J, Lefeuvre S, Oselin K et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008; 83: 452-459.
231. Goedecke VA, Clajus C, Burkhardt O et al. Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scand J Infect Dis 2009; 41: 155-157.
232. Allcock NM, Krueger TS, Manley HJ, Kumar VK, Abdallah J. Linezolid disposition during peritonitis: a case report. Perit Dial Int 2004; 24: 68-70.
233. Mimoz O, Petitpas F, Gregoire N, Gobin P, Marchand S, Couet W. Colistin distribution in the peritoneal fluid of a patient with severe peritonitis. Antimicrob Agents Chemother 2012; 56: 4035-4036.
234. Verdier MC, Seguin P, Le Touvet B, Cady A, Malledant Y, Tribut O. Ertapenem in plasma and peritoneal fluid from patients with severe intra-abdominal infections. J Antimicrob Chemother 2011; 66: 1934-1936.
235. Scheetz MH, Reddy P, Nicolau DP et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006; 40: 2064-2067.
236. Whitby M, Edwards R, Aston E, Finch RG. Pharmacokinetics of single dose intravenous vancomycin in CAPD peritonitis. J Antimicrob Chemother 1987; 19: 351-357.
237. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-164.
238. Bassetti M, Marchetti M, Chakrabarti A et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39: 2092-2106.
239. Bartoletti M, Cervera C, Hoyo I et al. Incidence and outcome of early Candida peritonitis after liver and pancreas transplantation. Mycoses 2013; 56: 162-167.